Circulating insulin-like growth factor binding protein-3 and risk of gastrointestinal malignant tumors.

Abstract

Insulin-like growth factor-1 (IGF1) is a potent mitogen and is inhibited by IGF-binding protein-3 (IGFBP3). High serum IGF1 and low IGFBP3 are associated with increased risk of several carcinomas. Here, we assessed the relationship of these peptides with the risk of gastrointestinal malignancies, in a prospective case-control study nested in the Japan Collaborative Cohort Study. The analysis involved 916 cases who had been diagnosed as gastrointestinal malignancies (C15-25) and 2306 controls. To estimate odds ratios for incidence of malignancies associated with these levels, a conditional logistic model was used. Both higher total and free IGFBP3 were associated with a decreased risk of tumor (P for trend <0.001 and =0.003, respectively). People in the second to fifth quintiles had lower risk compared to the first quintile (odds ratios ranged 0.532-0.650 and 0.582-0.725, respectively). After adjustment for IGF1, body mass index, drinking, and smoking, total IGFBP3 was inversely correlated with cancer risk (P for trend=0.031). After adjustment, free IGFBP3 was inversely associated with the risk (P for trend=0.007). Although total IGF1 was inversely correlated with tumor risk, it was not after controlling for IGFBP3 (P for trend=0.007 and 0.589, respectively). Free IGF1 was not associated with the risk (P for trend=0.361). Limiting subjects to those followed for over 3years reinforced the inverted relationships of total and free IGFBP3 with risk for tumors (P for trend=0.005 and 0.008, respectively). Both total and free IGFBP3 may be inversely associated with the incidence of gastrointestinal malignancies.